-
Oct 9, 2024 | 
touchendocrinology.com | Mahima Chillakanti |Elaine Young |April Hopcroft |Natalie Bellini
Overview BackgroundDiabetes during pregnancy is associated with significant maternal and foetal health risks. Insulin requirements also change during pregnancy. This necessitates careful and effective management of diabetes. Although commonly used in clinical practice, the US Food and Drug Administration (FDA)-approved algorithms for automated insulin delivery (AID) systems do not have pregnancy-specific glycaemic targets.
-
Jul 22, 2024 | 
diatribe.org | April Hopcroft
Diabetic retinopathy is the most common eye condition among people with diabetes. Many people don't show symptoms until the disease has progressed. Getting screened earlier can prevent disease and keep your eyes healthy in the long run.
-
Apr 29, 2024 | 
diatribe.org | April Hopcroft
Up to one-third of people who experience a heart attack will develop heart failure. In a large clinical trial of adults who had experienced a recent heart attack, Jardiance reduced the risk of hospitalizations for heart failure by 33%. Jardiance, Farxiga, and other SGLT-2 inhibitors have demonstrated many benefits in addition to improving A1C: namely, slowing kidney disease and protecting against heart failure.
-
Apr 29, 2024 | 
diatribe.org | April Hopcroft
Exercise snacks – short bursts of physical activity – can improve glycemic control and boost cardiovascular fitness. Experts share tips on how to incorporate exercise snacks into your daily routine. When you hear the words “exercise snacks,” you may think of a smoothie, a piece of fruit, or a protein bar. But exercise snacks aren't about what you eat or drink pre- or post-workout.
-
Apr 22, 2024 | 
diatribe.org | April Hopcroft
According to a recent update by the FDA, shortages for Lilly’s Mounjaro and Zepbound will persist through at least June 2024. New diabetes and weight loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound have made quite a splash at doctor’s offices, on TV, and even among TikTok influencers. In addition to their well-known weight loss effects, these drugs improve glycemic control and can protect the heart and kidneys.
-
Apr 22, 2024 | 
diatribe.org | April Hopcroft
The Behavioral Diabetes Institute is testing out a new diabetes education program for adults with type 2 diabetes throughout the U.S. Participants will receive financial compensation, diabetes supplies, and a personalized education plan. Trial Name: The AH-HA! Project: Enhancing the Benefits of Group Diabetes EducationDiabetes Type: Type 2 diabetesTrial Sponsor: Behavioral Diabetes Institute in San Diego, CAWhat is the trial researching?
-
Apr 15, 2024 | 
diatribe.org | April Hopcroft
A trial is recruiting adults with type 1 diabetes to investigate BMF-219, a new oral medication that stimulates beta cell growth. The drug has already shown promising results in type 2 diabetes, improving time in range and glycemic control. Clinical Trials Identifier: NCT06152042Trial Name: Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus (BF-MNN-112)Diabetes Type: Adults with type 1 diabetesTrial Sponsor: Biomea Fusion Inc. What is the trial researching?
-
Apr 8, 2024 | 
diatribe.org | April Hopcroft
The study is investigating whether an injectable drug, ZT-01, could prevent nighttime hypoglycemia in people with type 1 diabetes. Participate and shape the future of diabetes care. Clinical Trials Identifier: NCT05762107Trial Name: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes (ZONE)Diabetes Type: Adults with type 1 diabetesTrial Sponsor: Zucara TherapeuticsWhat is the trial researching?
-
Apr 1, 2024 | 
diatribe.org | April Hopcroft
Nausea and stomach problems are well-known side effects of GLP-1s, but you may be less familiar with other pros and cons of these powerful medications. With more and more people using GLP-1 receptor agonists for diabetes and weight management, healthcare providers are becoming more aware of ways – both positive and negative – these medications impact the body. Drug labels clearly warn GLP-1 users about unpleasant gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation.
-
Mar 29, 2024 | 
diatribe.org | April Hopcroft
Temporary shortages of the fast-acting insulin Humalog and its generic version may complicate diabetes care for people using pumps, automated insulin delivery, or on multiple daily injections. We spoke to experts about the best strategies to navigate insulin shortages. The FDA has listed two Lilly insulins on its drug shortage database: the 10 mL vials of the fast-acting insulin Humalog and its generic version, called Insulin Lispro Injection.
